CAR-T in solid tumors: Blazing a new trail through the brambles

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor-modified T cell (CAR-T) therapy has achieved significant success in treating hematologic malignancies.
• CAR-T therapy faces substantial hurdles in solid tumors, including infiltration into the tumor microenvironment (TME) and overcoming its inhibitory factors.

Purpose of the Study:

• To review the challenges and emerging strategies for applying CAR-T therapy in solid tumors.
• To provide a comprehensive overview of current problems and potential solutions in CAR-T development for solid tumor treatment.

Main Methods:

• This review synthesizes existing research on CAR-T therapy in solid tumors.
• It analyzes the obstacles related to TME infiltration and immune suppression.
• It discusses novel strategies designed to enhance CAR-T efficacy and safety in solid tumors.

Main Results:

• CAR-T therapy efficacy in solid tumors is limited by poor TME infiltration and the immunosuppressive nature of the tumor microenvironment.
• Various innovative strategies are being developed to improve CAR-T cell function within the TME.
• These strategies aim to enhance tumor recognition, persistence, and cytotoxic activity against solid tumors.

Conclusions:

• Despite significant challenges, advancements in CAR-T therapy for solid tumors are progressing rapidly.
• Emerging strategies offer promising avenues to overcome TME-related barriers and improve therapeutic outcomes.
• Further research and development are crucial for realizing the full potential of CAR-T therapy in solid tumor treatment.